{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:48:54Z","timestamp":1781300934606,"version":"3.54.1"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Hand-foot syndrome (HFS) is a common adverse event associated with lenvatinib treatment. Lenvatinib dose adjustment using therapeutic drug monitoring may be beneficial in the management of HFS, as symptoms improve with dose reduction or treatment interruption. The serum lenvatinib levels were monitored in a patient with lenvatinib-induced HFS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Case presentation:<\/jats:title>\n            <jats:p>A 74-year-old woman was administered lenvatinib (24 mg\/d) for papillary thyroid cancer. Although lenvatinib was withheld several times owing to the occurrence of HFS, the severity of the HFS was controlled to within grade 1 by reducing the dose to 4 mg\/d. The lenvatinib dose was subsequently increased to 8 mg\/d owing to the progression of lung metastases, resulting in increased HFS severity. The association between serum lenvatinib levels and the severity of HFS was examined in this case: serum lenvatinib levels were higher in grade 2 HFS than in grade 1 HFS (median 42.1 vs. 22.5 ng\/mL; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This case's findings suggest that serum lenvatinib concentrations are associated with the severity of lenvatinib-induced HFS and that there may be an overlap between drug concentrations, metastatic suppression, and the grade of HFS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001312","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T19:02:04Z","timestamp":1740769324000},"page":"323-325","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Serum Lenvatinib Concentration Monitoring in a Patient With Thyroid Cancer Exhibiting Hand-Foot Syndrome"],"prefix":"10.1097","volume":"47","author":[{"given":"Yusuke","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan;"},{"name":"Department of Pharmacy, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan;"},{"name":"Department of Pharmacy, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Sekine","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan;"},{"name":"Department of Pharmacy, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"R1-20250509","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med."},{"key":"R2-20250509","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"key":"R3-20250509","doi-asserted-by":"crossref","first-page":"25277","DOI":"10.18632\/oncotarget.25423","article-title":"Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients","volume":"9","author":"Numakura","year":"2018","journal-title":"Oncotarget"},{"key":"R4-20250509","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/1471-2407-14-530","article-title":"Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib","volume":"14","author":"Koyama","year":"2014","journal-title":"BMC Cancer"},{"key":"R5-20250509","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/FTD.0000000000000770","article-title":"High-performance liquid chromatography for therapeutic drug monitoring of serum lenvatinib","volume":"42","author":"Watanabe","year":"2020","journal-title":"Ther Drug Monit"},{"key":"R6-20250509","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12032-019-1263-3","article-title":"Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer","volume":"36","author":"Nagahama","year":"2019","journal-title":"Med Oncol"},{"key":"R7-20250509","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"R8-20250509","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/bcp.12907","article-title":"Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer","volume":"81","author":"Gupta","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20250509","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcph.398","article-title":"Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration","volume":"55","author":"Shumaker","year":"2015","journal-title":"J Clin Pharmacol."},{"key":"R10-20250509","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","article-title":"Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer","volume":"9","author":"Ozeki","year":"2019","journal-title":"Sci Rep."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T12:00:31Z","timestamp":1746792031000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001312","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"2024-06-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}